BRPI0917245A8 - Compostos derivados de isoquinolinona e sua composição farmacêutica - Google Patents
Compostos derivados de isoquinolinona e sua composição farmacêuticaInfo
- Publication number
- BRPI0917245A8 BRPI0917245A8 BRPI0917245A BRPI0917245A BRPI0917245A8 BR PI0917245 A8 BRPI0917245 A8 BR PI0917245A8 BR PI0917245 A BRPI0917245 A BR PI0917245A BR PI0917245 A BRPI0917245 A BR PI0917245A BR PI0917245 A8 BRPI0917245 A8 BR PI0917245A8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- derivative compounds
- isoquinolinone
- compounds
- isoquinolinone derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200801290 | 2008-09-15 | ||
DKPA200801290 | 2008-09-15 | ||
DKPA200900010 | 2009-01-06 | ||
DKPA200900010 | 2009-01-06 | ||
PCT/DK2009/050237 WO2010028655A1 (en) | 2008-09-15 | 2009-09-11 | Isoquinolinone derivatives as nk3 antagonists |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0917245A2 BRPI0917245A2 (pt) | 2015-11-10 |
BRPI0917245A8 true BRPI0917245A8 (pt) | 2018-08-14 |
BRPI0917245B1 BRPI0917245B1 (pt) | 2020-07-28 |
BRPI0917245B8 BRPI0917245B8 (pt) | 2021-05-25 |
Family
ID=41227186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0917245A BRPI0917245B8 (pt) | 2008-09-15 | 2009-09-11 | compostos derivados de isoquinolinona e sua composição farmacêutica |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP2342182B1 (pt) |
JP (1) | JP5536776B2 (pt) |
KR (1) | KR101638641B1 (pt) |
CN (1) | CN102149685B (pt) |
AR (1) | AR073511A1 (pt) |
AU (1) | AU2009291309B2 (pt) |
BR (1) | BRPI0917245B8 (pt) |
CA (1) | CA2732612C (pt) |
CL (1) | CL2011000533A1 (pt) |
CO (1) | CO6351781A2 (pt) |
CY (1) | CY1113743T1 (pt) |
DK (1) | DK2342182T3 (pt) |
EA (1) | EA021581B1 (pt) |
ES (1) | ES2399177T3 (pt) |
HR (1) | HRP20130038T1 (pt) |
IL (1) | IL210236A (pt) |
MX (1) | MX2011001786A (pt) |
MY (1) | MY164998A (pt) |
NZ (1) | NZ591265A (pt) |
PL (1) | PL2342182T3 (pt) |
PT (1) | PT2342182E (pt) |
RS (1) | RS52674B (pt) |
SI (1) | SI2342182T1 (pt) |
SM (1) | SMT201300020B (pt) |
TW (1) | TWI454461B (pt) |
WO (1) | WO2010028655A1 (pt) |
ZA (1) | ZA201103119B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008131779A1 (en) | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
US8415356B2 (en) | 2008-06-23 | 2013-04-09 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
CA2739946A1 (en) | 2008-10-20 | 2010-04-29 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
TW201143768A (en) | 2009-12-15 | 2011-12-16 | Lundbeck & Co As H | Pyridone derivatives as NK3 antagonists |
TW201144311A (en) * | 2010-03-12 | 2011-12-16 | Lundbeck & Co As H | Azaisoquionolinone derivatives as NK3 antagonists |
AU2012334011A1 (en) * | 2011-11-09 | 2014-05-15 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10A |
MX2020011376A (es) * | 2018-04-27 | 2021-02-09 | Sojournix Inc | Formas polimórficas y amorfas de isoquinolinona y métodos de uso de estas. |
CN118715209A (zh) * | 2022-02-10 | 2024-09-27 | 卡尔那生物科学株式会社 | 氟代异喹啉化合物及其制造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9825554D0 (en) * | 1998-11-20 | 1999-01-13 | Smithkline Beecham Spa | Novel Compounds |
EP1385839B1 (en) * | 2001-04-11 | 2006-02-22 | GlaxoSmithKline S.p.A. | 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
GB0509405D0 (en) * | 2005-05-10 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
WO2008131779A1 (en) * | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
-
2009
- 2009-09-11 KR KR1020117005880A patent/KR101638641B1/ko active IP Right Grant
- 2009-09-11 EP EP09776285A patent/EP2342182B1/en active Active
- 2009-09-11 PL PL09776285T patent/PL2342182T3/pl unknown
- 2009-09-11 ES ES09776285T patent/ES2399177T3/es active Active
- 2009-09-11 PT PT97762850T patent/PT2342182E/pt unknown
- 2009-09-11 MX MX2011001786A patent/MX2011001786A/es active IP Right Grant
- 2009-09-11 CN CN200980136727.XA patent/CN102149685B/zh not_active Expired - Fee Related
- 2009-09-11 AU AU2009291309A patent/AU2009291309B2/en not_active Ceased
- 2009-09-11 MY MYPI2011001144A patent/MY164998A/en unknown
- 2009-09-11 BR BRPI0917245A patent/BRPI0917245B8/pt not_active IP Right Cessation
- 2009-09-11 EA EA201170447A patent/EA021581B1/ru not_active IP Right Cessation
- 2009-09-11 DK DK09776285.0T patent/DK2342182T3/da active
- 2009-09-11 RS RS20130036A patent/RS52674B/en unknown
- 2009-09-11 WO PCT/DK2009/050237 patent/WO2010028655A1/en active Application Filing
- 2009-09-11 CA CA2732612A patent/CA2732612C/en not_active Expired - Fee Related
- 2009-09-11 JP JP2011526372A patent/JP5536776B2/ja not_active Expired - Fee Related
- 2009-09-11 NZ NZ591265A patent/NZ591265A/xx not_active IP Right Cessation
- 2009-09-11 SI SI200930492T patent/SI2342182T1/sl unknown
- 2009-09-14 AR ARP090103522A patent/AR073511A1/es active IP Right Grant
- 2009-09-14 TW TW098130900A patent/TWI454461B/zh not_active IP Right Cessation
-
2010
- 2010-12-23 IL IL210236A patent/IL210236A/en active IP Right Grant
-
2011
- 2011-03-04 CO CO11026657A patent/CO6351781A2/es not_active Application Discontinuation
- 2011-03-14 CL CL2011000533A patent/CL2011000533A1/es unknown
- 2011-04-28 ZA ZA2011/03119A patent/ZA201103119B/en unknown
-
2013
- 2013-01-17 HR HRP20130038AT patent/HRP20130038T1/hr unknown
- 2013-02-06 CY CY20131100105T patent/CY1113743T1/el unknown
- 2013-02-13 SM SM201300020T patent/SMT201300020B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201001639A1 (ru) | Композиции и способы их получения и применения | |
BRPI0917245A8 (pt) | Compostos derivados de isoquinolinona e sua composição farmacêutica | |
MA32161B1 (fr) | Formes de rifaximine et utilisations de celles-ci | |
UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
IN2012DN00971A (pt) | ||
EA201170349A1 (ru) | Модуляторы mif | |
EA201290836A1 (ru) | Связанные бис-арильные арилтриазолоны и их применение | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
BRPI0915084B8 (pt) | composto, e, composição farmacêutica | |
EA201000365A1 (ru) | Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза | |
MX2010007683A (es) | Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met. | |
GB201118656D0 (en) | New compounds | |
EA201301078A1 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
MY165579A (en) | Synthetic methods for spiro-oxindole compounds | |
MX343534B (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
EA201400392A1 (ru) | ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb | |
MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
EA201170753A1 (ru) | Налмефена гидрохлорид дигидрат | |
DE602007010764D1 (en) | Benzamidglucokinaseaktivatoren | |
EA200801580A1 (ru) | Новые производные пирониндола и способ их получения | |
MX2011006006A (es) | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: SOJOURNIX, INC. (US) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/07/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2687 DE 05-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |